Orchestration of CD4 T cell epitope preferences after multipeptide immunization

Journal of Immunology

Volumn 191, Issue 2, 2013, Pages 764-772

  Tung, Jacqueline ^a   Sant, Andrea J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL EXPANSION; CELL LOSS; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; GENETIC MODEL; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOMA; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; DIPHTHERIA TOXIN; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; IMMUNODOMINANT EPITOPES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; VACCINES, SUBUNIT;

EID: 84880104485     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300312     Document Type: Article

References (65)

1. Scharnagl, N. C., and C. S. Klade. 2007. Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches. Expert Rev. Vaccines 6: 605-615. (Pubitemid 47281302)
2. Nielsen, M., O. Lund, S. Buus, and C. Lundegaard. 2010. MHC class II epitope predictive algorithms. Immunology 130: 319-328.
3. Wang, P., J. Sidney, C. Dow, B. Mothé, A. Sette, and B. Peters. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLOS Comput. Biol. 4: e1000048.
4. Dudek, N. L., P. Perlmutter, M. I. Aguilar, N. P. Croft, and A. W. Purcell. 2010. Epitope discovery and their use in peptide based vaccines. Curr. Pharm. Des. 16: 3149-3157.
5. Sette, A., and J. Fikes. 2003. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15: 461-470. (Pubitemid 36934509)
6. Deluca, D. S., and R. Blasczyk. 2007. The immunoinformatics of cancer immunotherapy. Tissue Antigens 70: 265-271. (Pubitemid 47340739)
7. Slingluff, C. L., Jr. 2011. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 17: 343-350.
8. Mocellin, S., P. Pilati, and D. Nitti. 2009. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr. Med. Chem. 16: 4779-4796.
9. Kanodia, S., and W. M. Kast. 2008. Peptide-based vaccines for cancer: realizing their potential. Expert Rev. Vaccines 7: 1533-1545.
10. Mocellin, S. 2012. Peptides in melanoma therapy. Curr. Pharm. Des. 18: 820-831.
11. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457.
12. Purcell, A. W., J. McCluskey, and J. Rossjohn. 2007. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6: 404-414. (Pubitemid 46696551)
13. + T-cell help. Eur. J. Immunol. 42: 1080-1088.
14. Deng, H., L. Fosdick, and E. Sercarz. 1993. The involvement of antigen processing in determinant selection by class II MHC and its relationship to immunodominance. APMIS 101: 655-662. (Pubitemid 23338925)
15. Chen, W., and J. McCluskey. 2006. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell ?based cancer vaccines. Adv. Cancer Res. 95: 203-247. (Pubitemid 44066527)
16. Yewdell, J. W. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543. (Pubitemid 44529047)
17. Sant, A. J., F. A. Chaves, F. R. Krafcik, C. A. Lazarski, P. Menges, K. Richards, and J. M. Weaver. 2007. Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev. Vaccines 6: 357-368. (Pubitemid 46911599)
18. Sant, A. J., F. A. Chaves, S. A. Jenks, K. A. Richards, P. Menges, J. M. Weaver, and C. A. Lazarski. 2005. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 207: 261-278. (Pubitemid 41415023)
19. Ma, C., P. E. Whiteley, P. M. Cameron, D. C. Freed, A. Pressey, S. L. Chen, B. Garni-Wagner, C. Fang, D. M. Zaller, L. S. Wicker, and J. S. Blum. 1999. Role of APC in the selection of immunodominant T cell epitopes. J. Immunol. 163: 6413-6423.
20. Lazarski, C. A., F. A. Chaves, S. A. Jenks, S. Wu, K. A. Richards, J. M. Weaver, and A. J. Sant. 2005. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40. (Pubitemid 41019655)
21. Lazarski, C. A., F. A. Chaves, and A. J. Sant. 2006. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J. Exp. Med. 203: 1319-1328. (Pubitemid 43736600)
22. van Ham, S. M., U. Grüneberg, G. Malcherek, I. Bröker, A. Melms, and J. Trowsdale. 1996. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J. Exp. Med. 184: 2019-2024. (Pubitemid 26404492)
23. Schulze, M. S., and K. W. Wucherpfennig. 2012. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 24: 105-111.
24. Blum, J. S., C. Ma, and S. Kovats. 1997. Antigen-presenting cells and the selection of immunodominant epitopes. Crit. Rev. Immunol. 17: 411-417. (Pubitemid 27527390)
25. Nanda, N. K., and A. J. Sant. 2000. DM determines the cryptic and immunodominant fate of T cell epitopes. J. Exp. Med. 192: 781-788.
26. Karlsson, L. 2005. DM and DO shape the repertoire of peptide-MHC-class-II complexes. Curr. Opin. Immunol. 17: 65-70. (Pubitemid 40094016)
27. Nanda, N. K., and E. K. Bikoff. 2005. DM peptide-editing function leads to immunodominance in CD4 T cell responses in vivo. J. Immunol. 175: 6473-6480. (Pubitemid 41598889)
28. Weaver, J. M., F. A. Chaves, and A. J. Sant. 2009. Abortive activation of CD4 T cell responses during competitive priming in vivo. Proc. Natl. Acad. Sci. USA 106: 8647-8652.
29. McAdam, A. J., B. A. Pulaski, E. Storozynsky, K. Y. Yeh, J. Z. Sickel, J. G. Frelinger, and E. M. Lord. 1995. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell. Immunol. 165: 183-192.
30. Kim, J. M., J. P. Rasmussen, and A. Y. Rudensky. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8: 191-197. (Pubitemid 46152650)
31. Hou, D. Y., A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67: 792-801. (Pubitemid 46192220)
32. Kedl, R. M., J. W. Kappler, and P. Marrack. 2003. Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 15: 120-127. (Pubitemid 35454202)
33. + T cells expressing the same or different T cell receptors. Proc. Natl. Acad. Sci. USA 101: 3041-3046.
34. Blair, D. A., and L. Lefrançois. 2007. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl. Acad. Sci. USA 104: 15045-15050. (Pubitemid 47619590)
35. Willis, R. A., J. W. Kappler, and P. C. Marrack. 2006. CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc. Natl. Acad. Sci. USA 103: 12063-12068. (Pubitemid 44215811)
36. Ahmed, K. A., and J. Xiang. 2011. Mechanisms of cellular communication through intercellular protein transfer. J. Cell. Mol. Med. 15: 1458-1473.
37. Caumartin, J., J. Lemaoult, and E. D. Carosella. 2006. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl. Immunol. 17: 20-22. (Pubitemid 44828805)
38. Joly, E., and D. Hudrisier. 2003. What is trogocytosis and what is its purpose? Nat. Immunol. 4: 815. (Pubitemid 37098646)
39. Gascoigne, N. R., T. Zal, P. P. Yachi, and J. A. Hoerter. 2010. Co-receptors and recognition of self at the immunological synapse. Curr. Top. Microbiol. Immunol. 340: 171-189.
40. + regulatory T cells. Curr. Opin. Immunol. 16: 203-208.
41. Wing, K., and S. Sakaguchi. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11: 7-13.
42. + regulatory T cells under inflammatory or non-inflammatory conditions. Semin. Immunol. 23: 424-430.
43. Shevach, E. M. 2011. Biological functions of regulatory T cells. Adv. Immunol. 112: 137-176.
44. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
45. Sojka, D. K., and D. J. Fowell. 2011. Regulatory T cells inhibit acute IFN-γ synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc. Natl. Acad. Sci. USA 108: 18336-18341.
46. + regulatory T cell activity. J. Immunol. 175: 7274-7280.
47. Zhang, Y., R. Apilado, J. Coleman, S. Ben-Sasson, S. Tsang, J. Hu-Li, W. E. Paul, and H. Huang. 2001. Interferon γ stabilizes the T helper cell type 1 phenotype. J. Exp. Med. 194: 165-172. (Pubitemid 32673349)
48. + T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals. J. Immunol. 179: 939-949.
49. Liu, Y., and C. A. Janeway, Jr. 1990. Interferon γ plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J. Exp. Med. 172: 1735-1739.
50. Refaeli, Y., L. Van Parijs, S. I. Alexander, and A. K. Abbas. 2002. Interferon γ is required for activation-induced death of T lymphocytes. J. Exp. Med. 196: 999-1005.
51. Munn, D. H. 2006. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr. Opin. Immunol. 18: 220-225. (Pubitemid 43327306)
52. Terness, P., T. M. Bauer, L. Röse, C. Dufter, A. Watzlik, H. Simon, and G. Opelz. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196: 447-457.
53. Frumento, G., R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196: 459-468.
54. Munn, D. H., M. D. Sharma, J. R. Lee, K. G. Jhaver, T. S. Johnson, D. B. Keskin, B. Marshall, P. Chandler, S. J. Antonia, R. Burgess, et al. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297: 1867-1870. (Pubitemid 35024345)
55. + T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109: 3351-3359.
56. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
57. Baban, B., P. R. Chandler, M. D. Sharma, J. Pihkala, P. A. Koni, D. H. Munn, and A. L. Mellor. 2009. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183: 2475-2483.
58. Mellor, A. L., B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652-1655. (Pubitemid 36966447)
59. Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642. (Pubitemid 40719198)
60. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774. (Pubitemid 39336293)
61. Johnson, B. A., III, B. Baban, and A. L. Mellor. 2009. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 1: 645-661.
62. Lukacs-Kornek, V., D. Malhotra, A. L. Fletcher, S. E. Acton, K. G. Elpek, P. Tayalia, A. R. Collier, and S. J. Turley. 2011. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat. Immunol. 12: 1096-1104.
63. Lu, L., C. A. Bonham, F. G. Chambers, S. C. Watkins, R. A. Hoffman, R. L. Simmons, and A. W. Thomson. 1996. Induction of nitric oxide synthase in mouse dendritic cells by IFN-γ, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J. Immunol. 157: 3577-3586. (Pubitemid 126449172)
64. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2: 907-916. (Pubitemid 32976162)
65. Palucka, K., and J. Banchereau. 2012. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12: 265-277.